Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1982 1
1983 2
1984 2
1985 2
1989 2
1990 1
1991 2
1992 4
1993 1
1995 2
1996 3
1997 4
1998 3
1999 3
2000 4
2001 5
2002 6
2003 1
2004 7
2005 3
2006 3
2007 3
2008 5
2009 2
2010 5
2011 4
2012 7
2013 8
2014 5
2015 4
2016 4
2017 4
2018 3
2019 3
2020 2
2021 4
2022 3
2023 1
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

117 results

Results by year

Filters applied: . Clear all
Page 1
International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.
van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC. van Rhee F, et al. Among authors: schey s. Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4. Blood. 2018. PMID: 30181172 Free PMC article.
Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, Lindsay J, Weisel K, White D, Facon T, San Miguel J, Sunami K, O'Gorman P, Sonneveld P, Robak P, Semochkin S, Schey S, Yu X, Doerr T, Bensmaine A, Biyukov T, Peluso T, Zaki M, Anderson K, Dimopoulos M; OPTIMISMM trial investigators. Richardson PG, et al. Among authors: schey s. Lancet Oncol. 2019 Jun;20(6):781-794. doi: 10.1016/S1470-2045(19)30152-4. Epub 2019 May 13. Lancet Oncol. 2019. PMID: 31097405 Clinical Trial.
International evidence-based consensus diagnostic and treatment guidelines for unicentric Castleman disease.
van Rhee F, Oksenhendler E, Srkalovic G, Voorhees P, Lim M, Dispenzieri A, Ide M, Parente S, Schey S, Streetly M, Wong R, Wu D, Maillard I, Brandstadter J, Munshi N, Bowne W, Elenitoba-Johnson KS, Fössa A, Lechowicz MJ, Chandrakasan S, Pierson SK, Greenway A, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Chadburn A, Fajgenbaum DC. van Rhee F, et al. Among authors: schey s. Blood Adv. 2020 Dec 8;4(23):6039-6050. doi: 10.1182/bloodadvances.2020003334. Blood Adv. 2020. PMID: 33284946 Free PMC article.
The management of Castleman disease.
Lomas OC, Streetly M, Pratt G, Cavet J, Royston D, Schey S, Ramasamy K; British Society for Haematology (BSH) Committee. Lomas OC, et al. Among authors: schey s. Br J Haematol. 2021 Nov;195(3):328-337. doi: 10.1111/bjh.17688. Epub 2021 Aug 2. Br J Haematol. 2021. PMID: 34340261 No abstract available.
Widespread, waxy, coalescing cutaneous papules.
Maguire CA, Philippidou M, Schey S, Basu TN, Pembroke AC. Maguire CA, et al. Among authors: schey s. Clin Exp Dermatol. 2021 Dec;46(8):1626-1628. doi: 10.1111/ced.14659. Epub 2021 Sep 7. Clin Exp Dermatol. 2021. PMID: 34490932 No abstract available.
Pomalidomide therapy for myeloma.
Schey S, Ramasamy K. Schey S, et al. Expert Opin Investig Drugs. 2011 May;20(5):691-700. doi: 10.1517/13543784.2011.567265. Epub 2011 Mar 18. Expert Opin Investig Drugs. 2011. PMID: 21413906 Review.
Future directions in multiple myeloma treatment.
Child JA, Russell N, Sonneveld P, Schey S. Child JA, et al. Among authors: schey s. Acta Haematol. 2005;114 Suppl 1:8-13. doi: 10.1159/000087038. Acta Haematol. 2005. PMID: 16166766 Review.
Treatment of relapsed and refractory multiple myeloma in the era of novel agents.
van de Donk NW, Lokhorst HM, Dimopoulos M, Cavo M, Morgan G, Einsele H, Kropff M, Schey S, Avet-Loiseau H, Ludwig H, Goldschmidt H, Sonneveld P, Johnsen HE, Bladé J, San-Miguel JF, Palumbo A. van de Donk NW, et al. Among authors: schey s. Cancer Treat Rev. 2011 Jun;37(4):266-83. doi: 10.1016/j.ctrv.2010.08.008. Epub 2010 Sep 21. Cancer Treat Rev. 2011. PMID: 20863623 Review.
Position statement on the use of bortezomib in multiple myeloma.
Morgan GJ, Davies FE, Cavenagh JD, Jackson GH; United Kingdom Myeloma Forum (UKMF); Haematology Oncology Task Force of the British Committee for Standards in Haematology. Morgan GJ, et al. Int J Lab Hematol. 2008 Feb;30(1):1-10. doi: 10.1111/j.1751-553X.2007.01020.x. Int J Lab Hematol. 2008. PMID: 18190461 Review.
117 results